 "Bharat Biotech, Covaxin")
Covaxin manufacturer Bharat Biotech said that the detailed analysis of the phase-3 clinical trial data of its Covid-19 vaccine will be made public by July. The company is also doing phase-4 trials for real world effectiveness of vaccines, reports said.
In a series of tweets, Raches Ella, project lead, Covid19 vaccines at Bharat Biotech said that the last volunteer of their phase-3 clinical trial (sample size 25,800) was vaccinated in mid-March. “Mandatory CDSCO/FDA requirement of a two-month safety follow-up for all volunteers landed us in Mid May,” Ella said. He claimed that this was the largest efficacy trial conducted in
